PAVmed Inc. Series Z Warrant
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing… Read more
PAVmed Inc. Series Z Warrant (PAVMZ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.039x
Based on the latest financial reports, PAVmed Inc. Series Z Warrant (PAVMZ) has a cash flow conversion efficiency ratio of -0.039x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.58 Billion) by net assets ($40.93 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PAVmed Inc. Series Z Warrant - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how PAVmed Inc. Series Z Warrant's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PAVmed Inc. Series Z Warrant Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PAVmed Inc. Series Z Warrant ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CRFB3F
SA:CRFB3F
|
N/A |
|
LAND3F
SA:LAND3F
|
N/A |
|
BNK 1 Special Purpose Acquisition Co. Ltd.
KO:445360
|
N/A |
|
Tiger Reef Inc
PINK:TGRR
|
0.033x |
|
Record PLC
LSE:REC
|
0.126x |
|
ZIL Ltd
KAR:ZIL
|
N/A |
|
Acura Pharmaceuticals Inc
OTCQB:ACUR
|
1.415x |
|
HAPV3F
SA:HAPV3F
|
N/A |
Annual Cash Flow Conversion Efficiency for PAVmed Inc. Series Z Warrant (2014–2024)
The table below shows the annual cash flow conversion efficiency of PAVmed Inc. Series Z Warrant from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-7.03 Million | $-33.55 Million | 4.771x | +120.21% |
| 2023-12-31 | $-24.02 Million | $-52.04 Million | 2.167x | +133.37% |
| 2022-12-31 | $10.93 Million | $-70.98 Million | -6.492x | -1170.21% |
| 2021-12-31 | $79.42 Million | $-40.59 Million | -0.511x | -101.10% |
| 2020-12-31 | $-473.00K | $-21.91 Million | 46.330x | +1508.74% |
| 2019-12-31 | $-4.64 Million | $-13.36 Million | 2.880x | -18.85% |
| 2018-12-31 | $-2.48 Million | $-8.79 Million | 3.549x | +52.97% |
| 2017-12-31 | $-2.85 Million | $-6.61 Million | 2.320x | -83.38% |
| 2016-12-31 | $-319.07K | $-4.45 Million | 13.962x | +808.29% |
| 2015-12-31 | $633.92K | $-1.25 Million | -1.971x | -2499.63% |
| 2014-12-31 | $794.83K | $-60.27K | -0.076x | -- |